D-1013-2019 Class II Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-1013-2019 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Jan 18, 2019 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval. The recall status is terminated (terminated Apr 29, 2020). Affected quantity: 10,281 UD cartons.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2019
Initiation Date
Jan 18, 2019
Termination Date
Apr 29, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10,281 UD cartons

Product description

Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-788-20

Reason for recall

Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval.

Distribution pattern

Nationwide USA and Puerto Rico

Code information

Lots: 3095198, 3096266, 3098776, EXP 05-2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1013-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1013-2019. Report a data issue: hello@regdatalab.com.